Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

How brain tumors keep the beat - and why that makes them so dangerous

No. 72c | 15/12/2022

Scientists from Heidelberg University Hospital and the German Cancer Research Center describe tumor cells with pacemaker function in highly aggressive glioblastomas in "Nature" / pacemaker tumor cells promote growth and resistance of the brain tumor network / Research work within the framework of the UNITE research consortium under the leadership of the Neurological University Hospital Heidelberg

© Uniklinikum Heidelberg

Glioblastomas are highly aggressive brain tumors and literally tick differently than the healthy brain, as researchers at Heidelberg University Hospital (UKHD) and the German Cancer Research Center (DKFZ) recently reported in the journal Nature. They discovered that individual, particularly well-connected glioblastoma cells take on the function of pacemakers. From now on, they set the pace of activity signals for the entire tumor cell network. With serious consequences: The activity pattern activates two central molecular mechanisms in the tumor cells that drive the growth of the glioblastoma and increase its resistance. In addition, the team led by Professor Dr. Frank Winkler in the Clinical Cooperation Unit Neurooncology at UKHD and DKFZ identified the ion channel that gives tumor cells their pacemaker capabilities. This could provide a starting point for future therapies: In animal experiments, targeted inhibition slowed tumor growth and led to the death of parts of the tumor network.

Similar to cells in the healthy brain, the tumor cells of glioblastomas form extensive networks and thus infiltrate large parts of the brain. Due to these branching networks, they cannot be completely removed by surgery and survive intensive chemotherapy and radiotherapy. An important component of this organizational structure is the exchange of information between the tumor cells and input from neuronal activity. The research work of David Hausmann, a medical graduate student in Winkler's lab and first author of the article, focused on the internal communication of tumor cells: "We wanted to know what information the tumor cells pass on to each other - mainly via calcium signals - and how this is encoded - we wanted to understand the language of the tumor."

In specifically developed tumor models with human glioblastoma cells, e.g. in the form of mini-tumors in the culture dish as well as in brains of living mice, the researchers discovered a hierarchical organizational structure in addition to a basically existing "equal" mode of communication: individual cells of the network develop into pacemakers that dictate their periodic rhythmic activity to the others. In this context, the basic network structure of glioblastoma resembles that of the worldwide web in terms of communication efficiency: the pacemaker cells act as network nodes, i.e. they are particularly well connected with other tumor cells. They are equipped with specific ion channels - a prerequisite for rhythmic activity. "The tumor rhythm functions similarly to the heart rhythm. In fact, this ion channel, the calcium-dependent potassium channel KCa3.1, is also found in the pacemaker regions of the heart. But there it is only one among many," Hausmann explains.

Here's how it works: Electrically charged potassium ions flow in through the channel, which changes the surface tension of the cell - whether it's a heart cell, a neuron, or a tumor cell - and activates it. The activation signal is then transmitted to the network. What leads to muscle contraction and heartbeat in the heart results in the activation of two specific molecular mechanisms (MAPK and NF-κB) in glioblastomas, the researchers found. These are linked to the aggressive growth and resistance of glioblastomas. "The pacemaker cells transmit at a specific frequency, and that is apparently the activation code for exactly these two signaling pathways. In a sense, we have thus cracked the code of tumor communication," says senior author Prof. Winkler.

The research group showed that only a few percent of glioblastoma cells develop into pacemakers. When individual ones are targeted and turned off, the cells connected to them also die. "With the pacemakers, we have clearly discovered an Achilles' heel of glioblastomas," says Professor Dr. Wolfgang Wick, Medical Director of the Neurological Clinic at the UKHD and Head of Clinical Cooperation Unit Neurooncology. "If we can effectively block the KCa3.1 channel and thus turn off the pacemakers, this could permanently weaken the tumors and deprive them of the survival advantages of their network." A suitable drug candidate already exists, and initial tests in mice have been promising. However, clinical trials have yet to show whether it is suitable for therapy in humans.
The work was carried out as part of the Sonderforschungsbereich 1389 "Understanding and Targeting Resistance in Glioblastoma - UNITE". The spokesperson is Professor Dr. Wolfgang Wick.

References
Hausmann D, Hoffmann DC, Venkataramani V, Jung E, Horschitz S, Tetzlaff SK, Jabali A, Hai L,
Kessler T, Azorín DD, Weil S, Kourtesakis A, Sievers P, Habel A, Breckwoldt MO, Karreman M,
Ratliff M, Messmer JM, Yang Y, Reyhan E, Wendler S, Loeb C, Mayer C, Figarella K, Osswald
M, Solecki G, Sahm F, Garaschuk O, Kuner T, Koch P, Schlesner M, Wick W & Winkler F
(2022). Autonomous rhythmic activity in glioma networks drives brain tumor growth.
Nature. https://doi.org/10.1038/s41586-022-05520-4

Paper as PDF

More Information
https://www.klinikum.uni-heidelberg.de/neurologische-klinik/neurologie-und-poliklinik/behandlungsspektrum/schwerpunkt-neuroonkologie/ 
Winkler Lab at DKFZ: https://www.dkfz.de/en/neuroonkologie/AG_Winkler.html 

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS